Novavax (NVAX) Phase 3 Prepare Trial of ResVax for Prevention of RSV Disease in Infants Doesn't Meet Primary Endpoint
Go back to Novavax (NVAX) Phase 3 Prepare Trial of ResVax for Prevention of RSV Disease in Infants Doesn't Meet Primary EndpointNovavax, Inc. (NASDAQ: NVAX) | Delayed: 3.89 --0 (-0%) | |||||
---|---|---|---|---|---|---|
Previous Close | $3.89 | 52 Week High | $9.23 | |||
Open | $3.89 | 52 Week Low | $1.16 | |||
Day High | $3.99 | P/E | N/A | |||
Day Low | $3.81 | EPS | $-0.30 | |||
Volume | 2,861,577 |